Novo Nordisk A/S’s weekly shot that reduces obesity in adults returned promising results in teens, according to a study that adds to a growing wave of potential interventions for the stubborn condition.
Novo’s semaglutide, cleared last year as Wegovy for use in U.S. adults, lowered a measure of body fat by more than 16% in obese adolescents, according to draft results of the company-funded study released Nov. 2 by the New England Journal of Medicine.
Over 250 million children and adolescents will be overweight or obese by 2030, according to projections from World Obesity Federation. When chronic, those conditions can put people at elevated risk of heart disease, cancer and other dangerous disorders.
